# RedChemExpress

## Product Data Sheet

### Bupivacaine hydrochloride monohydrate

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-W415121 73360-54-0 C <sub>18</sub> H <sub>31</sub> ClN <sub>2</sub> O <sub>2</sub> 342.9 iGluR; Sodium Channel; Calcium Channel; Potassium Channel Membrane Transporter/Ion Channel; Neuronal Signaling Please store the product under the recommended conditions in the Certificate of	O NH H	1₂C 1CI
-	Analysis.	$\checkmark$	

Diological Activity			
Description	Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC <sub>50</sub> of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain <sup>[1][2][3]</sup> .		
IC <sub>50</sub> & Target	NMDA Receptor		
In Vitro	Bupivacaine inhibits NMDA receptor-mediated synaptic transmission in the dorsal horn of the spinal cord, an area critically involved in central sensitization <sup>[1]</sup> . Bupivacaine influences the voltage dependency of channel activation and steady-state inactivation by shifting the membrane potential of half-maximal activation/inactivation toward somewhat more negative membrane potentials. In their inactivated state, SCN5A channels are slightly sensitive toward Bupivacaine IC <sub>50</sub> =2.18±0.16 µM <sup>[2]</sup> . Bupivacaine reversibly inhibits the SK2 channel in a dose-dependent manner with the IC <sub>50</sub> of 16.5 µM <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

#### CUSTOMER VALIDATION

- Nat Commun. 2023 Jun 3;14(1):3224.
- Stem Cell Res Ther. 2021 Feb 4;12(1):107.
- Sci Rep. 2022 Jan 26;12(1):1378.

See more customer validations on <u>www.MedChemExpress.com</u>

#### REFERENCES

[1]. Meaghan A Paganelli, et al. Actions of Bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci. 2015 Jan 14;35(2):831-42.

[2]. Alexander P Schwoerer, et al. A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg. 2015 Jun;120(6):1226-34. [3]. Carsten Stoetzer, et al. Inhibition of Voltage-Gated Na<sup>+</sup> Channels by Bupivacaine Is Enhanced by the Adjuvants Buprenorphine, Ketamine, and Clonidine. Reg Anesth Pain Med.Jul/Aug 2017;42(4):462-468.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA